EPISODE · Aug 1, 2026 · 14 MIN
Exxon Mobil (XOM): Earnings Tripled and the Stock FELL — Is XOM Worth Buying?
from Charged Alpha Stock Encyclopedia · host Colton Thomas
Exxon Mobil Corporation (XOM) Q2 2026 — Revenue was ~$116.0B against a ~$98.4B consensus. GAAP earnings $14,525M ($3.48/sh) vs $4,183M ($1.00) in Q1; adjusted $14,680M ($3.52) — SHORT of the ~$3.68 estimate. Operating cash flow $23.6B; free cash flow $17,236M in one quarter — more than all of 2025's $23,612M. The stock closed $155.46, down 0.96% from $156.97, after running ~15% in thirty days. Earnings more than tripled sequentially — and almost none of it was the company's doing. Brent averaged roughly $103/bbl in Q2 (April $117, May ~$107, June $85) on the US-Iran conflict and disrupted Strait of Hormuz shipping. Underneath, execution was elite: a real Permian record above 1.8 Moebd on a planned 9% CAGR to 2030, Guyana at ~900 kbd gross with a fifth FPSO sailed for 4Q26 startup, and $16.3B of structural cost savings. But reported production FELL to 4,514 koebd, the 'highest in two decades' claim excludes lost Middle East volumes, and the $37.6B annualised distribution run-rate sits above our $29.0B mid-cycle owner free cash flow. An oil major's valuation is a price call as much as a company call, so we state our deck: Brent $72/bbl real. THE CALL: REDUCE (3/5, AN ELITE BUSINESS AT A WAR-PREMIUM PRICE) — base-case value ~$128.0 vs ~$155.46 today. KEY METRICS: - OUR CALL: REDUCE 3/5 — DCF fair value ~$128 vs the $155.46 close (-17.7%). Street: Hold, $167.85 avg (22 buy/28 hold/5 sell of 55); a wider ~30-analyst panel averages $173.32. Street low $123-$131 brackets ours. - DCF: mid-cycle owner FCF $29.0B at a Brent $72/bbl REAL deck; +6% 5yr (volume+cost, not price), +2.5% 5yr, 1.5% terminal, 8.0% discount -> EV $567.8B less ~$32B net debt / 4,175M shares = ~$128. Bear ($60 deck) $68 · Bull ($85 deck) $191 · prob-weighted $129. - REVERSE DCF: $155.46 requires mid-cycle owner FCF of $34.8B — a Brent deck near $80/bbl held flat in real terms forever — or a ~6.9% cost of capital. - CROSS-CHECK: on annualised Q2 it is 7.2x EV/DACF and a 10.6% FCF yield (looks cheap); on MID-CYCLE, 11.6x vs a 6-9x history and 4.8%. The mid-cycle DCF drives the verdict. - PRINT: revenue ~$116.0B vs ~$98.4B est. GAAP EPS $3.48 ($14,525M); adjusted EPS $3.52 ($14,680M) MISSED the ~$3.68 consensus. Q1 2026 was $1.00 GAAP / $2.09 adjusted. - CASH: FCF $17,236M in the quarter ($19,935M YTD vs $14,233M); cash capex $6,787M ($12,974M YTD). - SEGMENTS (adjusted): Upstream $9,189M (from $6,265M), Energy Products $4,099M (from $2,799M), Chemical $1,214M (from $110M), Specialty $969M (from $651M); corporate & financing -$791M. - PRODUCTION: 4,514 koebd, DOWN from 4,594 in Q1 — the 'highest in two decades' claim EXCLUDES lost Middle East volumes. Permian a genuine record >1.8 Moebd (9% CAGR to 2030); Guyana ~900 kbd gross, 5th FPSO sailed, +250 kbd 4Q26. - RETURNS: $9.4B distributed — $4.3B dividends + $5.1B buybacks ($37.6B annualised vs $29.0B mid-cycle owner FCF). Q3 dividend $1.03, payable Sep 10; $4.12/yr = 2.65% yield. Shares 4,331M -> ~4,175M. - BALANCE SHEET: $47.7B debt less $8.4B cash = $39.2B net debt (Mar 31), ~$32B pro forma; debt-to-capital under 16%. Structural cost savings $16.3B vs 2019, targeting $18B by 2030. - BACKDROP: Brent averaged ~$103 in Q2 (Apr $117, May ~$107, Jun $85) on the US-Iran/Hormuz disruption. Identified items: $1,365M reserve additions + $194M Middle East. What to watch: Bullish: Brent above $85 into 2027 without a conflict premium (-> ~$191), or Guyana FCF inflecting early. Bearish: buyback cut below $15B/yr, Permian growth under 9%, or Brent in the $60s two quarters running. We'd buy nearer ~$115 (~15x mid-cycle EPS, 3.6% yield). Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.
Embed this episode
NOW PLAYING
Exxon Mobil (XOM): Earnings Tripled and the Stock FELL — Is XOM Worth Buying?
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.